Guangjun Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guangjun Hou has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Wancun Zhang
Children’s Hospital Affiliated to Zhengzhou University
4 shared publications Ying Liang
Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, 450018, China
4 shared publicationsBang Du
Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, 450018, China
3 shared publications- Xianwei Zhang
Health Commission of Henan Province Key Laboratory for Precision Diagnosis and Treatment of Pediatric Tumor, Children’s Hospital Affiliated to Zhengzhou University, Zhengzhou, China
3 shared publications Huanmin Wang
Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Henan International Joint Laboratory for Pediatric Disease Prevention and Control, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, 450018, China
2 shared publicationsMengxin Zhang
Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Henan International Joint Laboratory for Pediatric Disease Prevention and Control, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, 450018, China
2 shared publications
Latest Publications
- 28 December 2022
- Published by Elsevier in Journal of Infection
- Vol. 86 (3) , e70-e71
Changes of Staphylococcus aureus infection in children before and after the COVID-19 pandemic, Henan, China
- 28 December 2022
- Published by Elsevier in Journal of Infection
- Vol. 86 (3) , e70-e71
Changes of Staphylococcus aureus infection in children before and after the COVID-19 pandemic, Henan, China
- 15 December 2022
- Published by Elsevier in Journal of Infection
- Vol. 86 (3) , 256-308
Changes of Mycoplasma pneumoniae infection in children before and after the COVID - 19 pandemic, Henan, China
- 15 December 2022
- Published by Elsevier in Journal of Infection
- Vol. 86 (3) , 256-308
Changes of Mycoplasma pneumoniae infection in children before and after the COVID - 19 pandemic, Henan, China
- 24 September 2022
- Published by Elsevier in Analytical Biochemistry
- Vol. 658, 114922
Dual isothermal amplification all-in-one approach for rapid and highly sensitive quantification of plasma circulating MYCN gene of neuroblastoma
- 24 September 2022
- Published by Elsevier in Analytical Biochemistry
- Vol. 658, 114922
Dual isothermal amplification all-in-one approach for rapid and highly sensitive quantification of plasma circulating MYCN gene of neuroblastoma
- Open Access
- 26 July 2022
- Published by Wiley in Cancer Reports
- Vol. 6 (2)
Plasma circulating cell‐free MYCN gene: A noninvasive and prominent recurrence monitoring indicator of neuroblastoma
The postoperative recurrence of neuroblastoma (NB) patients is an essential reason for the high mortality of NB due to the lack of early, non‐invasive, and dynamic strategies for monitoring NB recurrence. Therefore, whether the plasma circulating cell‐free MYCN gene as an indicator for monitoring of NB recurrence was systematically evaluated. The MYCN copy number and NAGK (reference gene) copy number (M/N) ratio in plasma and corresponding tumor tissues of NB patients was detected using an economical, sensitive, and specific single‐tube dual RT‐PCR approach developed in this study. The plasma M/N ratio of the MYCN gene amplification (MNA) group (N = 25, median M/N ratio = 4.90) was significantly higher than that of the non‐MNA group (N = 71, median M/N ratio = 1.22), p < .001. The M/N ratio in NB plasma (N = 60) was positively correlated with the M/N ratio in NB tumor tissue (N = 60), with a correlation coefficient of 0.9496. In particular, the results of dynamic monitoring of postoperative plasma M/N ratio of NB patients showed that an abnormal increase in M/N ratio could be detected 1–2 months before recurrence in NB patients. In summary, the single‐tube double RT‐PCR approach can be used to quantitatively detect MYCN copy number. The copy number of MYCN in the tissue and plasma of NB patients is consistent with each other. More importantly, the circulating cell‐free MYCN gene of NB patients can be used as a monitoring indicator for early, non‐invasive, and dynamic monitoring of NB recurrence.
- 26 July 2022
- Published by Wiley in Cancer Reports
- Vol. 6 (2)
Open AccessPlasma circulating cell‐free MYCN gene: A noninvasive and prominent recurrence monitoring indicator of neuroblastoma
The postoperative recurrence of neuroblastoma (NB) patients is an essential reason for the high mortality of NB due to the lack of early, non‐invasive, and dynamic strategies for monitoring NB recurrence. Therefore, whether the plasma circulating cell‐free MYCN gene as an indicator for monitoring of NB recurrence was systematically evaluated. The MYCN copy number and NAGK (reference gene) copy number (M/N) ratio in plasma and corresponding tumor tissues of NB patients was detected using an economical, sensitive, and specific single‐tube dual RT‐PCR approach developed in this study. The plasma M/N ratio of the MYCN gene amplification (MNA) group (N = 25, median M/N ratio = 4.90) was significantly higher than that of the non‐MNA group (N = 71, median M/N ratio = 1.22), p < .001. The M/N ratio in NB plasma (N = 60) was positively correlated with the M/N ratio in NB tumor tissue (N = 60), with a correlation coefficient of 0.9496. In particular, the results of dynamic monitoring of postoperative plasma M/N ratio of NB patients showed that an abnormal increase in M/N ratio could be detected 1–2 months before recurrence in NB patients. In summary, the single‐tube double RT‐PCR approach can be used to quantitatively detect MYCN copy number. The copy number of MYCN in the tissue and plasma of NB patients is consistent with each other. More importantly, the circulating cell‐free MYCN gene of NB patients can be used as a monitoring indicator for early, non‐invasive, and dynamic monitoring of NB recurrence.